Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Olaparib|DRUG: Placebo
Sponsor: AstraZeneca
Collaborators: Breast International Group|Frontier Science & Technology Research Foundation, Inc.|NRG Oncology|Myriad Genetic Laboratories, Inc.|Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet|Merck Sharp & Dohme LLC